NCIC Clinical Trials Group

Members / Participants Membership Information Clinical Trials Meetings
&
Education
Publications

Lectures
Correlative Science / Tumour Bank Notices Fellowships Committees Papaya Mango EDC BARL

2009

Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

18 December 2009

General

Canadian Cancer Trials Group Holiday Closures
The Canadian Cancer Trials Group Central Office will be closed with limited staff over the holidays beginning December 24, 2009. Please note that web-based applications (i.e. MANGO, GCP) will be available.
Read more ....

Cooperative Group Holiday Closures
We have collated other cooperative groups' holiday closures and have posted this information on the Canadian Cancer Trials Group website at www.ctg.queensu.ca.
Read more ....

Recent Publication
The primary publication for MAP.1 was recently published in Breast Cancer Research and Treatment.
Read more ....

Shipment of Specimens
Specimens that are collected for Canadian Cancer Trials Group trials and banked at the Canadian Cancer Trials Group Tumour Bank SHOULD NOT be shipped between December 17, 2009 and January 3, 2010 inclusive.
Read more ....

Operations

Canadian Cancer Trials Group Bulletin in the New Year
The next edition of the Canadian Cancer Trials Group Bulletin will be sent on Friday, January 8.
Read more ....

Trial Management Group

Changes to Trial Management Group (TMG)
An evaluation of TMG has resulted in a new trial team structure to help facilitate quality and efficiency in our trial management processes. Centres participating on our trials should check trial websites for current Canadian Cancer Trials Group contact info.
Read more ....

Trial Closure
One trial, IND.186, was recently closed.
Read more ....

Trial Activations
Two trials, IND.196 and IND.199, were recently activated.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

04 December 2009

Ethics Regulatory

Revised Participants List and Change Form
Revised Participants List and Change Form are now available.
Read more ....

General

Spring Meeting 2009 Expense Claims
Spring Meeting 2009 attendees who received funding support must submit their expense claims to Canadian Cancer Trials Group by 15 January 2010.
Read more ....

Changes in Organizational Structure at Central Office
Changes in the Canadian Cancer Trials Group's Central Office organizational structure and personnel have taken place.
Read more ....

Recent Publications
There were three recent publications -- one related to HN.4, one related to IND. 184, and the other a publication discussing the generalization of the results of cancer clinical trials. All are published online.
Read more ....

San Antonio Breast Cancer Symposium
Several Canadian Cancer Trials Group abstracts will be presented at the 32nd Annual San Antonio Breast Cancer Symposium being held December 9-13, 2009 in San Antonio, Texas.
Read more ....

Canadian Cancer Trials Group BR.10
An article and an associated editorial related to Canadian Cancer Trials Group BR.10 were published online by the Journal of Clinical Oncology and are both discussed in the current issue of the NCI Bulletin.
Read more ....

Operations

Primary Publications Search Utility
The Canadian Cancer Trials Group has created a website search utility where centres and trial participants can access primary publication citations of our trials and, where available, a link to the article pdf.
Read more ....

Trial Management Group

Trials Closed to Accrual
Two trials were recently closed to accrual -- IND.181 and CRC.2.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

20 November 2009

General

Recent Publications
There were four recent publications -- three trial-related (BR.24, CL.2, and MA.21), and one statistics publication.
Read more ....

American Society of Hematology (ASH) Annual Meeting
Several Canadian Cancer Trials Group abstracts will be presented at the 51st ASH Annual Meeting and Exposition being held December 5-8, 2009 in New Orleans.
Read more ....

Reminder -- "Complexity" Funding Available for BRC.5
In October 2008, the Canadian Cancer Trials Group informed centres that "complexity" funding is now available for BRC.5. Canadian centres will receive per case funding in the amount of $3000 per patient randomized to this study.
Read more ....

Maria Ricci Memorial Lectureship in Medical Oncology
Dr. Pam Goodwin is this year's guest speaker for the Maria Ricci Memorial Lectureship in Medical Oncology being held 25 November 2009 at the Cancer Research Institute, Queen's University.
Read more ....

Operations

US Cooperative Group Holiday Closures
The Thanksgiving Holiday in the United States is Thursday, November 26. Therefore, many of the US Cooperative Groups will be closed.
Read more ....

Trial Management Group

Trials Closed to Accrual
There were two trials recently closed to accrual -- BRC.4 and PR.12.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

06 November 2009

Ethics Regulatory

Changes to Canadian Cancer Trials Group Informed Consent Policies
The Ethics and Regulatory Office has made changes to its informed consent policies relating to signature requirements and submission.
Read more ....

Annual Re-Approvals
The Canadian Cancer Trials Group has amended its annual re-approval policy.
Read more ....

General

Recent Publications
There were three recent publications -- one related to MA.22 published in Breast Cancer Research and Treatment, and another related to BR.10, BR.18 and BR.21 published in Cancer.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

09 October 2009

General

Psychosocial Research Working Group
It is with regret that we announce the dissolution of the Psychosocial Research Working Group (PRWG).
Read more ....

Canadian Cancer Trials Group Office Closure
The Canadian Cancer Trials Group will be closed Monday, October 12, 2009 for Thanksgiving.
Read more ....

Operations

Reminder -- Fall Meeting Cancelled
As you will recall, this past July, we decided to cancel Fall Meeting.
Read more ....

OPEN -- New Initiative of the CTSU
Oncology Patient Enrollment Network (OPEN) is a new initiative of the Cancer Trials Support Unit (CTSU) to facilitate enrollment to Cooperative Group clinical trials.
Read more ....

Trial Management Group

MAP.3 October Newsletter
The October edition of the MAP.3 newsletter is now available!
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

25 September 2009

Trial Management Group

Trial Activation
Canadian Cancer Trials Group OV.21 was centrally activated 11 September 2009.
Read more ....

Trial Closure
Canadian Cancer Trials Group SRC.5/SWOG S0502 was closed to accrual on 18 September 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

11 September 2009

General

Recent Publications
There were two recent publications -- one discussing the role of international collaboration in improving cancer outcomes; the other discussing results of a pooled analysis of anticoagulation and bleeding in Canadian Cancer Trials Group trials BR.18, BR.20 and BR.21.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group BR.26 -- A Double-Blind Placebo Controlled Randomized Trial of PF-804 in Patients with Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease -- was centrally activated 4 September.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

28 August 2009

Ethics Regulatory

ER Policy Regarding Non-Essential Documentation
Occasionally centres submit documentation that Central Office is not required to retain. The Ethics and Regulatory Group may shred documents that are not required. Centres will not be notified if documents are shredded.
Read more ....

General

Holiday Office Closure
The Canadian Cancer Trials Group will be closed on Monday, September 7, 2009 for Labour Day. Regular business hours will resume on Tuesday, September 8 at 8:00 a.m. EDT.
Read more ....

NCI's Cooperative Groups National Meeting Report
Twice per year, the US Cancer Therapy Evaluation Program produces a report highlighting all of the Cooperative Groups' research in progress. The Canadian Cancer Trials Group contributes to this report by submitting information related to all of our CTEP-affiliated trials.
Read more ....

Recent Publications
There were three recent publications related to BR.10, PR.8, and IND.163.
Read more ....

Manual for Clinical Trials Nursing Recognized by AMWA
The Manual for Clinical Trials Nursing, 2nd edition has received Honorable Mention in the distinguished 2009 American Medical Writer's Association Medical Book Healthcare Professionals category. Monica Bacon, Canadian Cancer Trials Group Study Coordinator, is a co-editor.
Read more ....

Trial Management Group

Trial Closed to Accrual
IND.189 -- A phase II study of Interleukin-21 (rIL-21) in patients with metastatic or recurrent malignant melanoma -- was officially closed to accrual on August 17, 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

14 August 2009

General

Recent Publication
A recent study of the Canadian Cancer Trials Group's Working Group on Economic Analysis evaluating the cost-effectiveness of Cetuximab (Erbitux) in metastatic colorectal cancer has been published in the Journal of the National Cancer Institute.
Read more ....

Operations

Canadian Cancer Trials Group Name and Logo -- REMINDER
We would like to remind our members to ensure that any references to the "National Cancer Institute of Canada Clinical Trials Group" be replaced with "Canadian Cancer Trials Group".
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

04 August 2009

General

Highlighted Trial -- BRC.4
The current edition of the NCI Bulletin is highlighting BRC.4 -- A Phase III Randomized Study of Pemetrexed Disodium Versus Erlotinib Hydrochloride As Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Read more ....

Recent Publications
There were three recent publications -- two describing trial results (IND.170 and MA.12), and the other describing a study suggesting that abstracts presented at major scientific meetings often do not agree with the subsequent final analyses.
Read more ....

Operations

Canadian Cancer Trials Group Fall Meeting CANCELLED
The Canadian Cancer Trials Group Fall Meeting of Committees scheduled for October 17-18, 2009 in Montreal is cancelled.
Read more ....

Holiday Office Closure
Monday, August 3, 2009 is a Civic Holiday (in Canada), and the Canadian Cancer Trials Group will be closed. MANGO Patient Allocation System will be available. Regular business hours will resume on Tuesday, August 4 at 8:00 a.m. EDT.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group CEC.1/EORTC 26053-22054/RTOG 0834 -- Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial -- was centrally activated 22 July 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

17 July 2009

General

Single-Study Centres and DSMC Summary Reports -- REMINDER
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their REBs.
Read more ....

Leadership of the Canadian Cancer Trials Group Symptom Control Committee
Dr. Ray Viola, Co-Chair of the Symptom Control Committee since 2006, is stepping down.
Read more ....

Highlighted Trial -- MAC.13
The current edition of the NCI Bulletin includes an item discussing Canadian Cancer Trials Group MAC.13 (ALLTO) -- an international phase III clinical trial that aims to define the optimal treatment for early stage HER2-positive breast cancer.
Read more ....

Operations

Canadian Cancer Trials Group Fall Meeting CANCELLED
The Canadian Cancer Trials Group Fall Meeting of Committees scheduled for October 17-18, 2009 in Montreal is cancelled.
Read more ....

Trial Management Group

Trial Closed to Accrual
BI.1 -- A Phase III Study of Gemcitabine Plus Capecitabine (Gemcap) versus Gemcitabine Alone in Advanced Biliary Cancer -- was closed to accrual 14 July 2009.
Read more ....

Radioisotope Shortages -- Updated Trials Listing
As you know, the Canadian Cancer Trials Group has developed its own general principles on how to deal with the potential radioisotope shortage as it relates to Canadian Cancer Trials Group clinical trials. We have recently updated the listing of trials affected by the shortage.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

03 July 2009

Ethics Regulatory

Web-Based Ethics Utility
We are happy to announce that the Web-Based Ethics Utility will be available for use on Tuesday, July 7, 2009.
Read more ....

General

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their REBs.
Read more ....

Trial Management Group

Trial Closed to Accrual
MAC.7 (SWOG S0226) -- Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer -- was closed to accrual on 1 July 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

19 June 2009

General

Accomplishments of MA.5
MA.5 is a stellar example of a high quality Canadian Cancer Trials Group trial. And, as it is now permanently closed, it is fitting that the outstanding accomplishments that have resulted from this trial be recognized.
Read more ....

Holiday Office Closure
The Canadian Cancer Trials Group will be closed on Wednesday, July 1, 2009 in observance of Canada Day. Regular business hours will resume on Thursday, July 2 at 8:00 a.m. EDT.
Read more ....

Trial Management Group

Trials Closed to Accrual
Canadian Cancer Trials Group MA.22 was closed to accrual on 8 June 2009.
Read more ....

Permanent Study Closures
We are happy to inform you that three additional trials have now been deemed permanently closed -- MA.10, MA.5, and CO.3.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

05 June 2009

Ethics Regulatory

Canadian Cancer Trials Group Welcomes Mr. Scott Sawler
We are pleased to inform you that Mr. Scott Sawler has joined the staff of the Canadian Cancer Trials Group in the role of Ethics and Regulatory Manager.
Read more ....

General

Recent Publication
An article related to IND.152 was recently published in Clinical Lymphoma and Myeloma.
Read more ....

Dianne Johnston Is Retiring!
It is with a bittersweet reaction that we inform you that, after 23 years with the Canadian Cancer Trials Group, Dianne Johnston will be retiring.
Read more ....

Radioisotope Shortages
The Canadian Cancer Trials Group has developed some general principles on how to deal with the potential radioisotope shortage as it relates to Canadian Cancer Trials Group clinical trials.
Read more ....

Trial Management Group

Trials Closed to Accrual
Canadian Cancer Trials Group GAC.1 and IND.162 are now closed to accrual.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

22 May 2009

General

IND.189 Presented at the World Congress on Melanoma
Interim results of Canadian Cancer Trials Group IND.189 (A phase II study of Interleukin-21 (rIL-21) in patients with metastatic or recurrent malignant melanoma) show promising results and were recently presented at the World Congress on Melanoma in Vienna, Austria.
Read more ....

Canadian Cancer Trials Group ASCO 2009 Highlights
The Canadian Cancer Trials Group is presenting results from several trials at ASCO in Orlando, Florida, May 29-June 2, 2009. http://www.ctg.queensu.ca/public/publications/ASCO-2009MAY18.pdf
Read more ....

Canadian Cancer Trials Group CO.21 Trial Newsletter
The May 2009 edition of the Canadian Cancer Trials Group CO.21 Trial Newsletter is now available. And, congratulations to the Cancer Centre of Southeastern Ontario in Kingston for enrolling the study's first participant!
Read more ....

Highlighted Trial -- Canadian Cancer Trials Group PR.2
Long-awaited results from Canadian Cancer Trials Group PR.2 (SWOG 8794) show that men who received radiation therapy within 12 weeks of surgery delayed a recurrence of the cancer, and this led to longer survival compared with men who did not receive the treatment.
Read more ....

Trial Management Group

Permanent Study Closure: Part III - Intergroup-Led Trials
We are happy to inform you that a number of Intergroup-led trials, for which Canadian Cancer Trials Group is the Canadian sponsor, are complete and no longer require data submission or REB oversight as confirmed by the lead group.
Read more ....

Trials Closed to Accrual
Canadian Cancer Trials Group MA.17R was closed to accrual on 8 May 2009.
Read more ....

Trial Activation
BRC.4 -- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib -- was activated on 14 May 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

08 May 2009

General

Canadian Cancer Trials Group New Investigators Course
This 3-day course developed by the Canadian Cancer Trials Group and designed for new investigators with an interest in cancer clinical research will be held September 29 - October 2, 2009 in Kingston.
Read more ....

OICR Wants Your Input
The Ontario Institute for Cancer Research (OICR) is conducting a survey to discern fluency in vocabulary and comfort in evaluating molecular studies for diagnostic accuracy and clinical utility, and is asking for your help.
Read more ....

MA.5 -- Highlighted Trial & Recent Publication
Tumour samples from patients who participated on the Canadian Cancer Trials Group MA.5 trial show that alterations in the TOP2A gene were associated with better patient outcomes following anthracycline-based therapy compared with non-anthracycline-based therapy.
Read more ....

EDC and Study Account PINs
Sites should NOT use a generic PIN for their staff since this could be a security issue. Instead, each staff member using Electronic Data Capture (EDC) should have his/her own individual PIN.
Read more ....

Operations

Victoria Day Closure
The Canadian Cancer Trials Group will be closed on Monday, May 18, 2009 to celebrate Victoria Day. Regular business hours will resume on Tuesday, May 19 at 8:00 a.m. EDT.
Read more ....

Canadian Cancer Trials Group Website Password Requests
Tried to get onto the Canadian Cancer Trials Group's website and realized you've forgotten your password? You can now request online to have your password emailed to you. You can also change your Canadian Cancer Trials Group password to something that's more memorable!
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group MA.33/TROG 07.01 -- A Randomized Phase III Study oF Radiation Doses and Fractionation Schedules for Ductal Carcinoma In Situ (DCIS) of the Breast -- was centrally activated 29 April 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

24 April 2009

Ethics Regulatory

Initial Local Consent Form Review Process
Effective April 21, 2009, it is no longer mandatory that centres send their initial local consent forms to the Central Office for review prior to REB approval.
Read more ....

30/90 Day Safety Report Submission to Research Ethics Boards
Beginning April 24, 2009, clearer instructions to more explicitly reflect the timelines for REB submission will be available in the web-based safety reports monitoring utility, and the cover letters posted to the utility for safety reports.
Read more ....

General

Recent Publication
An article related to MA.24 was recently published in the Journal of Clinical Oncology.
Read more ....

Genitourinary Newsletter April 2009
The 2nd annual Genitourinary Newsletter is now available. This newsletter contains all sorts of helpful information and reminders to centres and investigators participating in Canadian Cancer Trials Group GU trials.
Read more ....

Highlighted Trial -- PR.11
Canadian Cancer Trials Group PR.11 (START trial) has been chosen for the April 2009 online issue of ASCO News & Forum.
Read more ....

Operations

Nurse Practitioners
Nurse practitioners who are formally credentialed will be permitted to participate in Canadian Cancer Trials Group trials as "clinical investigators".
Read more ....

Spring Meeting Trial Reports
2009 Spring Trial Reports are now available on the Canadian Cancer Trials Group members-only website using http://www.ctg.queensu.ca/trials/mtg-reports/2009/default.html
Read more ....

2009 Spring Meeting
The Canadian Cancer Trials Group 2009 Spring Meeting of Participants is scheduled for NEXT WEEK ... 30 April - 3 May at the Delta Chelsea Hotel in Toronto.
Read more ....

Trial Management Group

Trial Activations
Two trials were recently activated -- SC.22 and ALC.2.
Read more ....

Trial Closure
PRP.1B was closed 17 April 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

09 April 2009

Ethics Regulatory

Clinical Trial Site Information Form
Health Canada has recently revised its Clinical Trial Site Information (CTSI) form. As a result, Canadian Cancer Trials Group is no longer requiring centres to complete the "date of implementation" section of the Research Ethics Board Attestation (REBA).
Read more ....

General

Recent Publication
There was one recent publication in the journal Biomedical Informatics Insights.
Read more ....

Operations

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group will be closed on Friday, April 10, 2009 in observance of Good Friday. Regular business hours will resume on Monday, April 13 at 8:00 a.m. EDT.
Read more ....

Canadian Cancer Trials Group Spring Meeting Event -- Annual Cosbie Lecture
We are very pleased to announce Dr. Frances Shepherd as the 2009 "Cosbie Lecturer". Dr. Shepherd's talk is entitled "Lung Cancer: A Journey from Nihilism to Hope Through Bench to Bedside Research".
Read more ....

Canadian Cancer Trials Group Name and Logo -- REMINDER
On June 12, 2008, the Canadian Cancer Society Research Institue (CCSRI) Board of Directors voted unanimously in favour of integrating the NCIC with the Canadian Cancer Society (CCS). This has implications for our name -- the Canadian Cancer Trials Group.
Read more ....

2009 Spring Meeting of Participants
The Canadian Cancer Trials Group 2009 Spring Meeting of Participants is 30 April - 3 May at the Delta Chelsea Hotel in Toronto. Invitations have been sent out and attendees are asked to book their travel and hotel as soon as possible.
Read more ....

Trial Management Group

Trial Closure
IND.179 - A phase I study of CCI-779 in combination with Carboplatin and Paclitaxel in patients with advanced solid tumours - was closed 27 March 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

27 March 2009

General

Highlighted Trial -- CRC.5
CRC.5 - Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Read more ....

Recent Publication
A recent article related to CO.16 -- Randomized Trial Comparing Pre-Operative Radiotherapy and Selective Post-Operative Chemoradiotherapy in Rectal Cancer -- was published in The Lancet.
Read more ....

Operations

2009 Spring Meeting of Participants
The Canadian Cancer Trials Group 2009 Spring Meeting of Participants is scheduled for 30 April - 3 May at the Delta Chelsea Hotel in Toronto. Invitations have been sent out and attendees are asked to book their travel and hotel as soon as possible.
Read more ....

Trial Management Group

Trial Closure
IND.182 -- A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma -- was closed 24 March 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

13 March 2009

General

Canadian Cancer Trials Group Spring Meeting Event -- Annual Cosbie Lecture
We are very pleased to announce Dr. Frances Shepherd as the 2009 "Cosbie Lecturer".
Read more ....

Publications
There were three recent publications related to CO.17, IND.175, and CE.3.
Read more ....

CO.17 and Health-Related Quality of Life
Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
Read more ....

Survival Benefit from Brain Cancer Regimen Persists
Updated results of Canadian Cancer Trials Group CE.3 show that survival benefit from brain cancer regimen persists over time.
Read more ....

Highlighted Trial -- HN.6
Canadian Cancer Trials Group HN.6, an innovative phase III study in head and neck cancer, was activated in December 2008.
Read more ....

Operations

Canadian Cancer Trials Group Bulletin Archive
We've moved the link to the Canadian Cancer Trials Group Bulletins so that they are more readily accessible. The link, on the sidebar on the left side of the webpage, is http://www.ctg.queensu.ca/default.html.
Read more ....

Trial Management Group

Trial Activation
SRC.5 (SWOG S0502) -- A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors -- was centrally activated 27 February 2009.
Read more ....

Trial Closures
Two trials were recently closed -- CM.1 and LY.13.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

27 February 2009

General

Clinical Trials Committee -- Membership
We would like to update you about our Clinical Trials Committee (CTC) membership.
Read more ....

Operations

2009 Spring Meeting of Participants
The Canadian Cancer Trials Group 2009 Spring Meeting of Participants is scheduled for 30 April - 3 May at the Delta Chelsea Hotel in Toronto.
Read more ....

Spring Meeting Book
For the first time ever, there will be no paper Spring Meeting book.
Read more ....

Future Meetings
The 2010 and 2011 Canadian Cancer Trials Group Spring Meeting of Participants will be held in Montreal.
Read more ....

Trial Management Group

Study Closure of Canadian Cancer Trials Group-Led Studies Part II -- ADDENDUM
Recently, Canadian Cancer Trials Group identified another subset of Phase II/III Canadian Cancer Trials Group-led trials that are complete and no longer require data submission or REB oversight. We inadvertently omitted the Head and Neck trials.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

13 February 2009

General

Melanoma Site Committee
Dr. Michael Smylie has stepped down as Chair of the Melanoma Site Committee. Drs. Teresa Petrella and Alan Spatz will be taking over.
Read more ....

Brain Site Committee
Dr. Greg Cairncross has stepped down as Co-Chair of the Canadian Cancer Trials Group Brain Site Committee. Dr. Warren Mason will continue as the sole chair of the committee.
Read more ....

US Cooperative Group Holiday Closures
Several US cooperative groups will be closed on Monday, February 16, 2009 in observance of Presidents' Day.
Read more ....

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group will be closed on Monday, February 16, 2009 to celebrate Family Day. Regular business hours will resume on Tuesday, February 17 at 8:00 a.m. EDT.
Read more ....

Reminder to Centres Participating in MA.27
Centres are reminded that, as patients are approaching their ninth dispensation of MA.27 study treatment, the standard re-supply letter will request two pieces of information rather than one.
Read more ....

Publications
There were two recent publications -- Revised RECIST Guideline published in the European Journal of Cancer, and a Letter to the Editor of the Annals of Oncology in response to "Stopping a trial early in oncology: for patients or for industry?".
Read more ....

Trial Management Group

Permanent Study Closure of Canadian Cancer Trials Group-Led Studies -- Part II
Canadian Cancer Trials Group has identified another subset of Phase II/III Canadian Cancer Trials Group-led trials that are complete and no longer require data submission or REB oversight.
Read more ....

Trial Activation
Canadian Cancer Trials Group IND.190 -- A Phase I-II Trial of MK-0646, A Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor in Combination with Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer -- was centrally activated 30 January 2009.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

30 January 2009

General

Recent Publication
IND.164 -- A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination with Docetaxel in Advanced Breast Cancer -- was recently published in Clinical Cancer Research.
Read more ....

Operations

Canadian Cancer Trials Group Name and Logo
On June 12, 2008, the Canadian Cancer Society Research Institue (CCSRI) Board of Directors voted unanimously in favour of integrating the NCIC with the Canadian Cancer Society (CCS). This has implications for our name -- the Canadian Cancer Trials Group.
Read more ....

Reminder - Canadian Cancer Trials Group Participation on Open CTSU Studies
This is a reminder that for all US-led CTSU Menu studies (i.e., all trials ending in "C" ... e.g., MAC.13, etc.), Canadian Cancer Trials Group centres should participate directly through the Canadian Cancer Trials Group Central Office.
Read more ....

Trial Management Group

Trial Closure
MY.10 -- A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma -- will close to accrual today at 6pm EST.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

A bi-weekly Bulletin to notify participants at member centres of recent activities at Central Office, including summaries of recent trial activations/closures, upcoming meeting information, office closures, press releases, etc.

16 January 2009

General

Recent Publications
There were 4 recent publications.
Read more ....

Follow-Up Requirements for Closed IND Studies
A review of closed IND studies was undertaken recently, and the requirement for continued follow-up on these studies, and on IND studies in general, was discussed.
Read more ....

Bulletin Correction
A retrospective review of tumour cavitation and response assessment in NSCLC reported in the Journal of Clinical Oncology was conducted by Dr. Simon Crabb (not Dr. Simon Cragg as stated in the 19 December 2008 Bulletin).
Read more ....

Operations

US Cooperative Groups (and NCI PMB) Holiday Closures
Some US cooperative groups and the NCI Pharmaceutical Management Branch will be closed on Monday, January 19 for Martin Luther King Jr. Day, although some will offer limited services. Some groups are also closed on Tuesday, January 20 for Inauguration Day.
Read more ....

Trial Management Group

Trial Activations
Two trials were recently activated -- IND.186 (Phase II) and CL.3.
Read more ....

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletins